Lv12
45 积分 2025-12-22 加入
Cancer incidence and mortality in China, 2022
4小时前
已完结
Cancer incidence and mortality in China, 2022
4小时前
已关闭
NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025
10小时前
已完结
Non-Hodgkin lymphoma
1天前
已完结
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
1天前
已完结
Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first‐line treatment: A 15‐year follow‐up of patients with advanced follicular lymphoma in JCOG0203
1天前
已完结
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
1天前
已完结
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
1天前
已完结
Cost-effectiveness analysis of glofitamab versus rituximab for relapsed or refractory diffuse large B-cell lymphoma patients in China
16天前
已完结
Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma—a real-world multicenter retrospective cohort study
23天前
已完结
皖公网安备34019202002308
